Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,053 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis
Interventions: IDP-124 Lotion, IDP-124 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf); Biological
Lead sponsor: Shire; Industry
Eligibility: 1 Year and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 48
States / cities: Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more

Conditions: Hereditary Angioedema, HAE
Interventions: BCX4161, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Granada Hills, California + 21 more

Conditions: Irritable Bowel Syndrome
Interventions: True avoidance diet, Sham avoidance diet; Other
Lead sponsor: IBS-80, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: North Wales, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Dermatitis, Atopic, Rosacea, Acne Vulgaris, Sensitive Skin
Interventions: Non-marketed Cosmetic Facial Cleanser; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream 1%; Drug
Lead sponsor: Novartis; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 160 participants
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Conditions: Atopic Dermatitis, Eczema
Interventions: Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: Afimkibart; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • Alpharetta, Georgia + 3 more

Conditions: DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions: Cyclosporine, Methylprednisolone and Prednisone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hives
Interventions: 2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor; Drug
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Sarcoma
Interventions: diagnostic imaging; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Bleach Bath and Moisturizers; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 8 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Allergy
Interventions: Skin Testing; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Atopic Dermatitis
Interventions: REGN3500, REGN3500-Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Atopic Dermatitis
Interventions: Oregano extract cream, Hydrocortisone; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 2 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Atopic Dermatitis, Eczema
Interventions: SAN007 5% cream, Placebo, SAN007 10% cream; Drug
Lead sponsor: Santalis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Austin, Texas • Bryan, Texas • San Antonio, Texas

Conditions: Melanoma
Interventions: VivaScope System; Device
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hereditary Angioedema
Interventions: C1 Esterase Inhibitor; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 6 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 13
States / cities: Weston, Florida • Atlanta, Georgia • Idaho Falls, Idaho + 10 more

Conditions: Atopic Dermatitis
Interventions: Actigraphy Device; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Maplewood, Missouri

Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions: ATTO-3712, Placebo; Drug
Lead sponsor: Attovia Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more

Conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Duarte, California • La Jolla, California • Denver, Colorado + 16 more

Conditions: Non-infectious Uveitis
Interventions: AIN457, AIN 457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 20
States / cities: Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Atopic Dermatitis
Interventions: LEO 138559, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Fountain Valley, California • Los Angeles, California • San Francisco, California + 9 more

Search by objective public record fields.

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

IBS Skin Patch Test Food Allergy Study

A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants

Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

Cardamom and Topical Roseomonas in Atopic Dermatitis

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Cyclosporine Vs Steroids in DRESS

Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline

Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma

The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis

Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Scratching Validation Study

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Safety and Efficacy of AIN457 in Noninfectious Uveitis

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis